High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: A dilemma of specific prevention

Early Human Development

Volumn 88, Issue SUPPL.2, 2012, Pages

  Manzoni, P ^a   Paes, B ^b   Resch, B ^c   Mejias, A ^d   Ramilo, O ^d   Carbonell Estrany, X ^e   Bont, L ^f  

^a S ANNA HOSPITAL   (Italy)

^b MCMASTER UNIVERSITY   (Canada)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d NATIONWIDE CHILDREN S HOSPITAL   (United States)

^e HOSPITAL CLÍNIC   (Spain)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Down syndrome; Immune deficiency; Neuromuscular disease; Palivizumab; Respiratory syncytial virus

Indexed keywords

IMMUNOGLOBULIN; PALIVIZUMAB; RIBAVIRIN;

ASTHMA; BONE MARROW TRANSPLANTATION; CLINICAL FEATURE; CLINICAL PRACTICE; COMORBIDITY; CONGENITAL DIAPHRAGM HERNIA; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DOWN SYNDROME; DYSPHAGIA; FORCED EXPIRATORY FLOW; HEALTH CARE COST; HIGH RISK INFANT; HOSPITAL READMISSION; HOSPITALIZATION COST; HUMAN; IMMUNE DEFICIENCY; INFANT MORTALITY; INFECTION PREVENTION; INFECTION SENSITIVITY; INNATE IMMUNITY; MORBIDITY; NEUROMUSCULAR DISEASE; PREMATURITY; RARE DISEASE; RESPIRATORY SYNCYTIAL VIRUS BRONCHIOLITIS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; RISK FACTOR; SUDDEN INFANT DEATH SYNDROME; UNSPECIFIED SIDE EFFECT; WHEEZING;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; BRONCHIOLITIS; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; RARE DISEASES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES;

EID: 84861470949     PISSN: 03783782     EISSN: 18726232     Source Type: Journal    
DOI: 10.1016/S0378-3782(12)70012-9     Document Type: Review

References (124)

1. Resch B, Manzoni P, Lanari M Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes. Paediatr Resp Rev 2009, 10:148-153.
2. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009, 360:588-598.
3. Arnold SR, Wang EE, Law BJ, Boucher FD, Stephens D, Robinson JL, et al. Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatr Infect Dis J 1999, 18:866-869. Pediatric Investigators Collaborative Network on Infections in Canada.
4. Panitch HB Viral respiratory infections in children with technology dependence and neuromuscular disorders. Pediatr Infect Dis J 2004, 23:S222-S227.
5. Wilkesmann A, Ammann RA, Schildgen O, et al. Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course. Pediatr Infect Dis J 2007, 26:485-491.
6. Millner ME, de la Monte SM, Hutchins GM Fatal respiratory syncytial virus infection in severe combined immunodeficiency syndromes. Am J Dis Child 1985, 139:1111-1114.
7. Hall CB, Powell KR, MacDonald NE, Gala CL, Menegus ME, Suffin SC, et al. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med 1986, 315:77-81.
8. Chandwani S, Borkowsky W, Krasinski K, Lawrence R, Welliver R Respiratory syncytial virus infection in human immunodeficiency virus-infected children. J Pediatr 1990, 117:251-254.
9. King JC, Burke AR, Clemens JD, Nair P, Farley JJ, Vink PE, et al. Respiratory syncytial virus illnesses in human immunodeficiency virus- and noninfected children. Pediatr Infect Dis J 1993, 12:733-739.
10. Schneider S, Borzy MS Fatal respiratory syncytial virus pneumonia as the presenting feature of severe combined immunodeficiency disease. Clin Pediatr (Phila) 1996, 35:147-149.
11. Madhi SA, Schoub B, Simmank K, Blackburn N, Klugman KP Increased burden of respiratory viral associated severe lower respiratory tract infections in children infected with human immunodeficiency virus type-1. J Pediatr 2000, 137:78-84.
12. Resch B Palivizumab for the prophylaxis of respiratory syncytial virus infection. Pediatr Health 2008, 2:265-278.
13. The IMpact-RSV Study Group Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998, 102(3 Pt 1):531-537.
14. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH, Cardiac Synagis Study Group, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003, 143:532-540.
15. American Academy of Paediatrics Prevention of respiratory syncytial virus infections: indications for use of palivizumab and update on the use of RSV-IGIV. Paediatrics 1998, 102:1211-1216.
16. Committee on Infectious Diseases From the American Academy of Pediatrics: Policy statements - Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009, 124:1694-1701.
17. Resch B, Berger A, Urlesberger B, Müller WD, for Arbeitsgruppe Neonatologie und pädiatrische Intensivmedizin der österreichischen Gesellschaft für Kinder- und Jugendheilkunde Empfehlungen zur Respiratory Syncytial Virus Prophylaxe bei Frühgeborenen mit Palivizumab (Synagis®) - Update 2003. Monatsschr Kinderheilkd 2004, 152:223-224. In German.
18. Raccomandazioni della Societa' Italiana di Neonatologia per la prevenzione delle malattie da VRS Aggiornamento 2004 (redatto a cura del Consiglio Direttivo della SIN). Acta Neonatol Pediatr 2004, 18:19-29.
19. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010, 375:1545-1555.
20. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003, 289:179-186.
21. Sampalis JS Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr 2003, 143:S150-S156.
22. Panickar JR, Dodd SR, Smyth RL, Couriel JM Trends in deaths from respiratory illness in children in England and Wales from 1968 to 2000. Thorax 2005, 60:1035-1038.
23. Smyth RL, Openshaw PJ Bronchiolitis. Lancet 2006, 368:312-322.
24. Fernández-Rodríguez A, Ballesteros S, de Ory F, Echevarría JE, Alvarez-Lafuente R, Vallejo G, et al. Virological analysis in the diagnosis of sudden children death: a medico-legal approach. Forensic Sci Int 2006, 161:8-14.
25. Bajanowski T, Rolf B, Jorch G, Brinkmann B Detection of RNA viruses in sudden infant death (SID). Int J Legal Med 2003, 117:237-240.
26. Carbonell-Estrany X, Quero J Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons. Pediatr Infect Dis J 2001, 20:874-879.
27. Fauroux B Special populations. Paediatr Respir Rev 2009, 10:21-22.
28. Broughton S, Roberts A, Fox G, Pollina E, Zuckerman M, Chaudhry S, et al. Prospective study of healthcare utilisation and respiratory morbidity due to RSV infection in prematurely born infants. Thorax 2005, 60:1039-1044.
29. Simões EA, Carbonell-Estrany X, Fullarton JR, Liese JG, Figueras-Aloy J, Doering G, European RSV Risk Factor Study Group, et al. A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP Study. Respir Res 2008, 9:78.
30. Bont L, Steijn M, Van Aalderen WM, Brus F, Th Draaisma JM, Van Diemen-Steenvoorde RA, et al. Seasonality of long term wheezing following respiratory syncytial virus lower respiratory tract infection. Thorax 2004, 59:512-516.
31. Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13. Lancet 1999, 354:541-545.
32. Sigurs N, Aljassim F, Kjellman B, Robinson PD, Sigurbergsson F, Bjarnason R, et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax 2010, 65:1045-1052.
33. Ruotsalainen M, Piippo-Savolainen E, Hyvärinen MK, Korppi M Respiratory morbidity in adulthood after respiratory syncytial virus hospitalization in infancy. Pediatr Infect Dis J 2010, 29:872-874.
34. Bont L, Steijn M, van Aalderen WM, Kimpen JL Impact of wheezing after respiratory syncytial virus infection on health-related quality of life. Pediatr Infect Dis J 2004, 23:414-417.
35. Willson DF, Landrigan CP, Horn SD, Smout RJ Complications in infants hospitalized for bronchiolitis or respiratory syncytial virus pneumonia. J Pediatr 2003, 143:S142-S149.
36. Bloemers BL, van Furth AM, Weijerman ME, Gemke RJ, Broers CJ, van den Ende K, et al. Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis - a prospective birth-cohort study. Pediatrics 2007, 120:e1076-e1081.
37. El Saleeby CM, Somes GW, DeVincenzo JP, Gaur AH Risk factors for severe RSV disease in children with cancer: the importance of lymphopenia and young age. Pediatrics 2008, 121:235-243.
38. Simoes EAF Respiratory syncytial virus infection. Lancet 1999, 354:847-852.
39. MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA Respiratory syncytial virus infection in infants with congenital heart disease. N Engl J Med 1982, 307:397-400.
40. Horn SD, Smout RJ Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr 2003, 143:S133-S141.
41. Simoes EAF Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr 2003, 143:S118-S126.
42. Figueras-Aloy J, Carbonell-Estrany X, Quero J, IRIS Study Group Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalisation in premature infants born at a gestational age of 33-35 weeks in Spain. Pediatr Infect Dis J 2004, 23:815-820.
43. Figueras-Aloy J, Carbonell-Estrany X, Quero-Jiménez J, Fernández-Colomer B, Guzmán-Cabañas J, Echaniz-Urcelay I, IRIS Study Group, et al. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J 2008, 27:788-793.
44. Law BJ, Langley JM, Allen U, Paes B, Lee DS, Mitchell I, et al. The pediatric investigators collaborative network on infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J 2004, 23:806-814.
45. Doering G, Gusenleitner W, Belohradsky BH, Burdach S, Resch B, Liese JG The risk of respiratory syncytial virus-related hospitalizations in preterm infants of 29 to 35 weeks gestational age. Pediatr Infect Dis J 2006, 25:1188-1190.
46. Sampalis JS, Langley J, Carbonell-Estrany X, Paes B, O'Brien K, Allen U, et al. Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation. Med Decis Making 2008, 28:471-480.
47. Simões EA, Carbonell-Estrany X, Fullarton JR, Rossi GA, Barberi I, Lanari M, European RSV Risk Factor Study Group European risk factors' model to predict hospitalization of premature infants born 33-35 weeks' gestational age with respiratory syncytial virus: validation with Italian data. J Matern Fetal Neonatal Med 2011, 24:152-157.
48. Carbonell-Estrany X, Simões EA, Fullarton JR, Ferdynus C, Gouyon JB, European RSV Risk Factor Study Group Validation of a model to predict hospitalization due to RSV of infants born at 33-35 weeks' gestation. J Perinat Med 2010, 38:411-417.
49. Stensballe LG, Fullarton JR, Carbonell-Estrany X, Simões EA Population based external validation of a European predictive model for respiratory syncytial virus hospitalization of premature infants born 33 to 35 weeks of gestational age. Pediatr Infect Dis J 2010, 29:374-376.
50. Lanctôt KL, Masoud ST, Paes BA, Tarride JE, Chiu A, Hui C, et al. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis. Curr Med Res Opin 2008, 24:3223-3237.
51. Lázaro y de Mercado P, Figueras Aloy J, Doménech Martínez E, Echániz Urcelay I, Closa Monasterolo R, Wood Wood MA, et al. [The efficiency (cost-effectiveness) of palivizumab as prophylaxis against respiratory syncytial virus infection in premature infants with a gestational age of 32-35 weeks in Spain]. An Pediatr (Barc) 2006, 65:316-324. In Spanish.
52. Resch B, Sommer C, Nuijten MJ, Seidinger S, Walter E, Schoellbauer V, et al. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children based on long-term epidemiological data from Austria. Pediatr Infect Dis J 2012, 31(1):e1-e8.
53. Rossi GA, Medici MC, Arcangeletti MC, Lanari M, Merolla R, Paparatti UD, Osservatorio RSV Study Group, et al. Risk factors for severe RSV-induced lower respiratory tract infection over four consecutive epidemics. Eur J Pediatr 2007, 166:1267-1272.
54. Boyce TG, Mellen BG, Mitchel EF, Wright PF, Griffin MR Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr 2000, 137:865-870.
55. Wang EE, Law BJ, Stephens D Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr 1995, 126:212-219.
56. Simoes EA, Groothuis JR Respiratory syncytial virus prophylaxis - the story so far. Respir Med 2002, 96:S15-S24.
57. Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M, Boron M, Palivizumab Outcomes Registry Group Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol 2008, 28:511-517.
58. Paes BA, Li A, Lanctot KL, Mitchell I A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants. Value Health 2011, 14(7):A398. (abstract PIH4).
59. Resch B, Gusenleitner W, Müller WD, Haas J Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29-32 weeks. Eur J Clin Microbiol Infect Dis 2006, 25:120-122.
60. Mori M, Kawashima H, Nakamura H, Nakagawa M, Kusuda S, Saji T, Surveillance Committee for Severe RSV Infection, et al. Nationwide survey of severe respiratory syncytial virus infection in children who do not meet indications for palivizumab in Japan. J Infect Chemother 2011, 17:254-263.
61. Zachariah P, Ruttenber M, Simões EA Down syndrome and hospitalizations due to respiratory syncytial virus: a population-based study. J Pediatr 2011, [Epub ahead of print].
62. Kristensen K, Stensballe LG, Bjerre J, Roth D, Fisker N, Kongstad T, et al. Risk factors for respiratory syncytial virus hospitalisation in children with heart disease. Arch Dis Child 2009, 94:785-789.
63. Afghani B, Ngo T Severe respiratory syncytial virus infection in term infants with genetic or other underlying disorders. Pediatrics 2008, 121:868-869.
64. Megged O, Schlesinger Y Down syndrome and respiratory syncytial virus infection. Pediatr Infect Dis J 2010, 29:672-673.
65. Cohen AH, Boron ML, Dingivan C. A phase IV study of the safety of Synagis (palivizumab) for prophylaxis of respiratory syncytial virus disease in children with cystic fibrosis. Presented at International Conference of The American Thoracic Society, May 20-25, 2005, San Diego, CA (abstract A53).
66. Abman SH, Ogle JW, Butler-Simon N, Rumack CM, Accurso FJ Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J Pediatr 1988, 113:826-830.
67. Armstrong D, Grimwood K, Carlin JB, Carzino R, Hull J, Olinsky A, et al. Severe viral respiratory infections in infants with cystic fibrosis. Pediatr Pulmonol 1998, 26:371-379.
68. Giebels K, Marcotte JE, Podoba J, Rousseau C, Denis MH, Fauvel V, et al. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis. Pediatr Pulmonol 2008, 43:169-174.
69. Masumoto K, Nagata K, Uesugi T, Yamada T, Kinjo T, Hikino S, et al. Risk of respiratory syncytial virus in survivors with severe congenital diaphragmatic hernia. Pediatr Int 2008, 50:459-463.
70. Madhi SA, Kuwanda L, Cutland C, Klugman KP Five-year cohort study of hospitalization for respiratory syncytial virus associated lower respiratory tract infection in African children. J Clin Virol 2006, 36:215-221.
71. Sung L, Alonzo TA, Gerbing RB, Aplenc R, Lange BJ, Woods WG, Children's Oncology Group, et al. Respiratory syncytial virus infections in children with acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer 2008, 51:784-786.
72. Navas L, Wang E, de Carvalho V, Robinson J Improved outcome of respiratory syncytial virus infection in a high-risk hospitalised population of Canadian children. J Pediatr 1992, 121:348-354. Pediatric Investigators Collaborative Network on Infections in Canada.
73. Thorburn K Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus (RSV) infection. Arch Dis Child 2009, 94:99-103.
74. Schechter MS Airway clearance applications in infants and children. Respir Care 2007, 52:1382-1390.
75. Resch B, Berger A, Bernert G, Eber E, Frischer T, Simma B, et al. Konsensuspapier zur Prophylaxe der RSV-Infektion mit Palivizumab und Post-RSV-Atemwegs-erkrankung. Monatsschr Kinderheilkd 2008, 156:381-383. In German.
76. Bertrand P, Navarro H, Caussade S, Holmgren N, Sánchez I Airway anomalies in children with Down syndrome: endoscopic findings. Pediatr Pulmonol 2003, 36:137-141.
77. Schloo BL, Vawter GF, Reid LM Down syndrome: patterns of disturbed lung growth. Hum Pathol 1991, 22:919-923.
78. Shah PS, Hellmann J, Adatia I Clinical characteristics and follow up of Down syndrome infants without congenital heart disease who presented with persistent pulmonary hypertension of newborn. J Perinat Med 2004, 32:168-170.
79. Kusters MA, Verstegen RH, Gemen EF, de Vries E Intrinsic defect of the immune system in children with Down syndrome: a review. Clin Exp Immunol 2009, 156:189-193.
80. Sly PD, Brennan S, Gangell C, de Klerk N, Murray C, Mott L, Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST-CF), et al. Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med 2009, 180:146-152.
81. Hiatt PW, Grace SC, Kozinetz CA, Raboudi SH, Treece DG, Taber LH, et al. Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics 1999, 103:619-626.
82. Wang EE, Prober CG, Manson B, Corey M, Levison H Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis. N Engl J Med 1984, 311:1653-1658.
83. Colasurdo GN, Fullmer JJ, Elidemir O, Atkins C, Khan AM, Stark JM Respiratory syncytial virus infection in a murine model of cystic fibrosis. J Med Virol 2006, 78:651-658.
84. Van Ewijk BE, Wolfs TF, Aerts PC, Van Kessel KP, Fleer A, Kimpen JL, et al. RSV mediates Pseudomonas aeruginosa binding to cystic fibrosis and normal epithelial cells. Pediatr Res 2007, 61:398-403.
85. de Vrankrijker AM, Wolfs TF, Ciofu O, Høiby N, van der Ent CK, Poulsen SS, et al. Respiratory syncytial virus infection facilitates acute colonization of Pseudomonas aeruginosa in mice. J Med Virol 2009, 81:2096-2103.
86. Stark JM, Stark MA, Colasurdo GN, LeVine AM Decreased bacterial clearance from the lungs of mice following primary respiratory syncytial virus infection. J Med Virol 2006, 78:829-838.
87. Speer ME, Fernandes CJ, Boron M, Groothuis JR Use of palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis. Pediatr Infect Dis J 2008, 27:559-561.
88. McCormick J, Southern KW A survey of palivizumab for infants with cystic fibrosis in the UK. Arch Dis Child 2007, 92:87-88.
89. Giusti R North American Synagis prophylaxis survey. Pediatr Pulmonol 2009, 44:96-98.
90. Lin AE, Pober BR, Adatia I Congenital diaphragmatic hernia and associated cardiovascular malformations: type, frequency, and impact on management. Am J Med Genet C Semin Med Genet 2007, 145C:201-216.
91. Peetsold MG, Heij HA, Kneepkens CM, Nagelkerke AF, Huisman J, Gemke RJ The long-term follow-up of patients with a congenital diaphragmatic hernia: a broad spectrum of morbidity. Pediatr Surg Int 2009, 25:1-17.
92. Muratore CS, Kharasch V, Lund DP, Sheils C, Friedman S, Brown C, et al. Pulmonary morbidity in 100 survivors of congenital diaphragmatic hernia monitored in a multidisciplinary clinic. J Pediatr Surg 2001, 36:133-140.
93. Abolmaali N, Koch A, Götzelt K, Hahn G, Fitze G, Vogelberg C Lung volumes, ventricular function and pulmonary arterial flow in children operated on for left-sided congenital diaphragmatic hernia: long-term results. Eur Radiol 2010, 20:1580-1589.
94. Peetsold MG, Heij HA, Nagelkerke AF, Ijsselstijn H, Tibboel D, Quanjer PH, et al. Pulmonary function and exercise capacity in survivors of congenital diaphragmatic hernia. Eur Respir J 2009, 34:1140-1147.
95. Kamata S, Usui N, Kamiyama M, Tazuke Y, Nose K, Sawai T, et al. Long-term follow-up of patients with high-risk congenital diaphragmatic hernia. J Pediatr Surg 2005, 40:1833-1838.
96. Wischermann A, Holschneider AM, Hübner U Long-term follow-up of children with diaphragmatic hernia. Eur J Pediatr Surg 1995, 5:13-18.
97. Cortes RA, Keller RL, Townsend T, Harrison MR, Farmer DL, Lee H, et al. Survival of severe congenital diaphragmatic hernia has morbid consequences. J Pediatr Surg 2005, 40:36-45.
98. Strunk T, Simmer K, Kikiros C, Patole S Late-onset right-sided diaphragmatic hernia in neonates - case report and review of the literature. Eur J Pediatr 2007, 166:521-526.
99. Prasse JE, Kikano GE An overview of pediatric dysphagia. Clin Pediatr (Phila) 2009, 48:247-251.
100. Friedman B, Frazier JB Deep laryngeal penetration as a predictor of aspiration. Dysphagia 2000, 15:153-158.
101. Sheikh S, Stephen T, Howell L, Eid N Gastroesophageal reflux in infants with wheezing. Pediatr Pulmonol 1999, 28:181-186.
102. Tighe MP, Beattie RM Managing gastro-oesophageal reflux in infancy. Arch Dis Child 2010, 95:243-244.
103. Khoshoo V, Edell D Previously healthy infants may have increased risk of aspiration during respiratory syncytial viral bronchiolitis. Pediatrics 1999, 104:1389-1390.
104. Kim CK, Kim HB, Kurian T, Chung JY, Yoo Y, Koh YY Increased laryngeal lavage lipid-laden macrophage index during acute bronchiolitis. Acta Paediatr 2007, 96:1025-1029.
105. Hernandez E, Khoshoo V, Thoppil D, Edell D, Ross G Aspiration: a factor in rapidly deteriorating bronchiolitis in previously healthy infants?. Pediatr Pulmonol 2002, 33:30-31.
106. Panigada S, Sacco O, Girosi D, Tomà P, Rossi GA Recurrent severe lower respiratory tract infections in a child with abnormal tracheal morphology. Pediatr Pulmonol 2009, 44:192-194.
107. Boeckh MJ, Gooley T, Englund J, Chien J, Crawford SW, Bowden R, et al. Respiratory syncytial virus (RSV) infection in hematopoietic stem cell transplant (HCT) recipients: risk factors for acquisition and lower respiratory tract disease, and impact on mortality. Blood 2004, 104(11):57A. (abstract 187).
108. Ebbert JO, Limper AH Respiratory syncytial virus pneumonitis in immunocompromised adults: clinical features and outcome. Respiration 2005, 72:263-269.
109. Liu B, Kimura Y Local immune response to respiratory syncytial virus infection is diminished in senescence-accelerated mice. J Gen Virol 2007, 88:2552-2558.
110. King JC Community respiratory viruses in individuals with human immunodeficiency virus infection. Am J Med 1997, 102:19-24.
111. Manzoni P, Leonessa M, Farina D, Gomirato G Respiratory syncytial virus infection and prophylaxis with palivizumab in immunosuppressed children: the experience of a large Italian neonatal care setting. Pediatr Transplant 2007, 11:456-457.
112. Meissner HC Selected populations at increased risk from respiratory syncytial virus infection. Pediatr Infect Dis J 2003, 22:S40-S44.
113. Harrington RD, Hooton TM, Hackman RC, Storch GA, Osborne B, Gleaves CA, et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis 1992, 165:987-993.
114. Avetisyan G, Mattsson J, Sparrelid E, Ljungman P Respiratory syncytial virus infection in recipients of allogeneic stem-cell transplantation: a retrospective study of the incidence, clinical features, and outcome. Transplantation 2009, 88:1222-1226.
115. Ljungman P Respiratory virus infections in bone marrow transplant recipients: the European perspective. Am J Med 1997, 102:44-47.
116. Campbell AP, Chien JW, Kuypers J, Englund JA, Wald A, Guthrie KA, et al. Respiratory virus pneumonia after hematopoietic cell transplantation (HCT): associations between viral load in bronchoalveolar lavage samples, viral RNA detection in serum samples, and clinical outcomes of HCT. J Infect Dis 2010, 201:1404-1413.
117. Torres JP, Gomez AM, Khokhar S, Bhoj VG, Tagliabue C, Chang ML, et al. Respiratory syncytial virus (RSV) RNA loads in peripheral blood correlates with disease severity in mice. Respir Res 2010, 11:125.
118. Boeckh M, Berrey MM, Bowden RA, Crawford SW, Balsley J, Corey L Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis 2001, 184:350-354.
119. Chávez-Bueno S, Mejías A, Merryman RA, Ahmad N, Jafri HS, Ramilo O Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients. Pediatr Infect Dis J 2007, 26:1089-1093.
120. DeVincenzo JP, Hirsch RL, Fuentes RJ, Top FH Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation - a compassionate use experience. Bone Marrow Transplant 2000, 25:161-165.
121. Ramilo O Evolution of prophylaxis: MoAb, siRNA, vaccine, and small molecules. Paediatr Respir Rev 2009, 10:23-25.
122. Manzoni P, Leonessa ML, Galletto P, Gallo E, Sala U, Gomirato G, et al. Use of palivizumab in neonates who do not meet the American Academy of Pediatrics guidelines for respiratory syncytial virus prophylaxis. Early Hum Dev 2009, 85:S93.
123. Cohen AH, Bomar R, Cohen LE, Lesnick B, Civgi V, Kirchner K, et al. RSV prophylaxis using palivizumab in 86 high-risk children, outside of AAP red book guidelines. Presented at American Pediatrics Society/Society for Pediatric Research Annual Meeting; 28 April-1 May 2001, Baltimore, MD, USA (abstract 2656).
124. Paes B, Mitchell I, Li A, Lanctôt KL Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations. Eur J Pediatr 2011, [Epub ahead of print]. 10.1007/s00431-011-1654-8.